1-9 of 9
Carla M.L. van Herpen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Laurien J. Zeverijn, Birgit S. Geurts, Thomas W. Battaglia, Jade M. van Berge Henegouwen, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Myriam Chalabi, Carla M.L. van Herpen, Lot A. Devriese, Frans L.G. Erdkamp, Mariette Labots, Maja J.A. de Jonge, Emile D. Kerver, Adriaan D. Bins, Lindsay V.M. Leek, Jessica C.L. Notohardjo, Alfonsus J.M. van den Eertwegh, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Joris van de Haar, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4339–4351.
https://doi.org/10.1158/1078-0432.CCR-24-0480
Published: 01 October 2024
View article titled, The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Open the PDF for The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, Jade M. van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M.L. Jansen, Wendy W.J. de Leng, Maja J.A. de Jonge, Ann Hoeben, Carla M.L. van Herpen, Hans M. Westgeest, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3735–3746.
https://doi.org/10.1158/1078-0432.CCR-24-0011
Published: 03 September 2024
View article titled, Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Open the PDF for Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M.E. Desar, C. Willemien Menke-van der Houven van Oordt, Astrid A.M. van der Veldt, Anne I.J. Arens, Adrienne H. Brouwers, Bertha Eisses, Peter F.A. Mulders, Otto S. Hoekstra, Gerben J.C. Zwezerijnen, Winette T.A. van der Graaf, Erik H.J.G. Aarntzen, Wim J.G. Oyen, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 592–601.
https://doi.org/10.1158/1078-0432.CCR-22-0921
Published: 01 February 2023
View article titled, [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Open the PDF for [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

Martin Schuler, Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow, Filip Y.F.L. De Vos, Carla M.L. van Herpen, Matteo S. Carlino, Douglas B. Johnson, Carola Berking, Micaela B. Reddy, Allison S. Harney, Jordan D. Berlin, Rodabe N. Amaria
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3002–3010.
https://doi.org/10.1158/1078-0432.CCR-21-3872
Published: 15 July 2022
View article titled, Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <em>NRAS</em>-mutant Melanoma
Open the PDF for Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <em>NRAS</em>-mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination

Sasja F. Mulder, Joannes F.M. Jacobs, Michel A.M. Olde Nordkamp, Joep M.D. Galama, Ingrid M.E. Desar, Ruurd Torensma, Steven Teerenstra, Peter F.A. Mulders, Kris C.P. Vissers, Cornelis J.A. Punt, I. Jolanda M. de Vries, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (13): 4541–4549.
https://doi.org/10.1158/1078-0432.CCR-11-0253
Published: 05 July 2011
View article titled, Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination
Open the PDF for Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination in another window
Includes: Supplementary data
Journal Articles

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, S. Gail Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille V. Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1613–1623.
https://doi.org/10.1158/1078-0432.CCR-09-2483
Published: 28 February 2010
View article titled, The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Open the PDF for The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)

Hanneke W.M. van Laarhoven, Walter Fiedler, Ingrid M.E. Desar, Jack J.A. van Asten, Sandrine Marréaud, Denis Lacombe, Anne-Sophie Govaerts, Jan Bogaerts, Peter Lasch, Johanna N.H. Timmer-Bonte, Antonio Lambiase, Claudio Bordignon, Cornelis J.A. Punt, Arend Heerschap, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1315–1323.
https://doi.org/10.1158/1078-0432.CCR-09-1621
Published: 15 February 2010
View article titled, Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
Open the PDF for Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041) in another window
Journal Articles

Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor

Carla M.L. van Herpen, Jeroen A.W.M. van der Laak, I. Jolanda M. de Vries, Johan H. van Krieken, Peter C. de Wilde, Michiel G.J. Balvers, Gosse J. Adema, Pieter H.M. De Mulder
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (5): 1899–1909.
https://doi.org/10.1158/1078-0432.CCR-04-1524
Published: 08 March 2005
View article titled, Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor
Open the PDF for Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor in another window